Drug interactions between afatinib and nintedanib
Interactions between your drugs
There were no interactions found in our database between afatinib and nintedanib - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
- Afatinib is in the drug class multikinase inhibitors.
- Afatinib is used to treat Non-Small Cell Lung Cancer.
- Nintedanib is a member of the drug class multikinase inhibitors.
- Nintedanib is used to treat Idiopathic Pulmonary Fibrosis.
Drug and food interactions
Applies to: afatinib
Food may reduce the absorption of afatinib, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take afatinib at least 1 hour before or 2 hours after a meal.
Applies to: nintedanib
Food may help the absorption of nintedanib. You should take this medication with food and swallow it whole with liquid. Chewing or crushing the medication can leave a bitter taste.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:
Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.